Anti-MLKL (phospho S345) 抗体 [EPR9515(2)]
Anti-MLKL (phospho S345) antibody [EPR9515(2)]
- RabMAb
- Recombinant
- 20ul selling size
- 了解详情
4
(27 Reviews)
|
(404 Publications)
Anti-MLKL (phospho S345) antibody [EPR9515(2)] (ab196436) is a rabbit monoclonal antibody detecting MLKL in Western Blot, IP, Dot Blot. Suitable for Mouse.
- Clone EPR9515(2) is the most cited clone to MLKL
- Biophysical QC for unrivalled batch-batch consistency
- Over 280 publications
查看别名
Mixed lineage kinase domain-like protein, Mlkl
- WB
Lab
Western blot - Anti-MLKL (phospho S345) antibody [EPR9515(2)] (AB196436)
Blocking and dilution buffer : 5% NFDM/TBST.
All lanes:
Western blot - Anti-MLKL (phospho S345) antibody [EPR9515(2)] (ab196436) at 1/1000 dilution
Lane 1:
Untreated L-929 (Mouse connective tissue fibroblast cells) whole cell lysate at 10 µg
Lane 2:
L-929 whole cell lysate treated with 20 ng/ml TNF alpha (<a href='/products/proteins-peptides/recombinant-human-tnf-alpha-protein-ab9642'>ab9642</a>), 100 nM Smac mimetic, and 20 µM z-VAD (<a href='/products/biochemicals/z-vadoh-fmk-irreversible-general-caspase-inhibitor-ab120382'>ab120382</a>) for 8 h and then harvested. at 10 µg
Secondary
All lanes:
Peroxidase-conjugated goat anti-rabbit IgG (H+L) at 1/1000 dilution
Predicted band size: 54 kDa
Observed band size: 54 kDa
false
Exposure time: 15s
- WB
Lab
Western blot - Anti-MLKL (phospho S345) antibody [EPR9515(2)] (AB196436)
Blocking and diluting buffer : 5% NFDM/TBST.
MLKL pS345 is a trigger for necroptosis. It is only detectable in infection/cellular damaged (PMID : 29229989) or aging tissue (PMID : 28807105) but not in normal tissues.
All lanes:
Western blot - Anti-MLKL (phospho S345) antibody [EPR9515(2)] (ab196436) at 1/1000 dilution
Lane 1:
L-929 treated with 20 ng/ml TNF alpha (<a href='/products/proteins-peptides/recombinant-human-tnf-alpha-protein-ab9642'>ab9642</a>), 100 nM Smac mimetic, and 20 µM z-VAD (<a href='/products/biochemicals/z-vadoh-fmk-irreversible-general-caspase-inhibitor-ab120382'>ab120382</a>) for 8 h, whole cell lysate at 20 µg
Lane 2:
Mouse brain tissue lysate at 20 µg
Lane 3:
Mouse colon tissue lysate at 20 µg
Lane 4:
Mouse lung tissue lysate at 20 µg
Lane 5:
Mouse retina tissue lysate at 20 µg
Lane 6:
Mouse liver tissue lysate at 20 µg
Lane 7:
Raw264.7 (Mouse Abelson murine leukemia virus-induced tumor macrophage) whole cell lysate at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution
Predicted band size: 54 kDa
Observed band size: 54 kDa
false
Exposure time: 50s
- WB
Supplier Data
Western blot - Anti-MLKL (phospho S345) antibody [EPR9515(2)] (AB196436)
Blocking and diluting buffer : 5% NFDM/TBTS.
ab181602 was used as a loading control at 1/1000000 dilution.
We recommend involving downstream protein p-MLKL as a control to validate the stimulation of p-RIP3.
Lanes 1 - 4:
Western blot - Anti-RIP3 (phospho T231 + S232) antibody [2D7] (<a href='/products/primary-antibodies/rip3-phospho-t231-s232-antibody-2d7-ab205421'>ab205421</a>) at 1/1000 dilution
Lanes 5 - 8:
Western blot - Anti-MLKL (phospho S345) antibody [EPR9515(2)] (ab196436) at 1/1000 dilution
Lanes 1, 3, 5 and 7:
Untreated L-929 (mouse connective tissue fibroblast cell line) whole cell lysate at 20 µg
Lanes 2 and 6:
L-929 (mouse connective tissue fibroblast cell line) treated with 20 ng/ml TNF-a, 100 nM Smac mimetic and 20 μM z-VAD for 8 hours whole cell lysate at 20 µg
Lanes 4 and 8:
L-929 (mouse connective tissue fibroblast cell line) treated with 20 ng/ml TNF-a, 100 nM Smac mimetic and 20 μM z-VAD for 6 hours whole cell lysate at 20 µg
Secondary
Lanes 1 - 4:
Peroxidase-Conjugated Goat anti-Mouse IgG (H+L) at 1/20000 dilution
Lanes 5 - 8:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution
Predicted band size: 57 kDa,54 kDa
Observed band size: 53 kDa
false
Exposure time: 180s
- WB
Supplier Data
Western blot - Anti-MLKL (phospho S345) antibody [EPR9515(2)] (AB196436)
Blocking and diluting buffer concentration : 5% NFDM/TBST.
ab181602 GAPDH was used as a loading control at 1/1000000 dilution.
We recommend involving downstream protein p-MLKL as a control to validate the stimulation of p-RIP3.
Lanes 1 - 4:
Western blot - Anti-RIP3 (phospho T231 + S232) antibody [EPR19403-52] (<a href='/products/primary-antibodies/rip3-phospho-t231-s232-antibody-epr19403-52-ab222320'>ab222320</a>) at 1/1000 dilution
Lanes 5 - 8:
Western blot - Anti-MLKL (phospho S345) antibody [EPR9515(2)] (ab196436) at 1/1000 dilution
Lanes 1, 3, 5 and 7:
Untreated L-929 (mouse connective tissue fibroblast cell line) whole cell lysate at 20 µg
Lanes 2 and 6:
L-929 (mouse connective tissue fibroblast cell line) treated with 20 ng/ml TNF-a, 100 nM Smac mimetic and 20 μM z-VAD for 8 hours whole cell lysate at 20 µg
Lanes 4 and 8:
L-929 (mouse connective tissue fibroblast cell line) treated with 20 ng/ml TNF-a, 100 nM Smac mimetic and 20 μM z-VAD for 6 hours whole cell lysate at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution
Predicted band size: 57 kDa,54 kDa
Observed band size: 53 kDa
false
Exposure time: 180s
- WB
Supplier Data
Western blot - Anti-MLKL (phospho S345) antibody [EPR9515(2)] (AB196436)
Blocking and diluting buffer : 5% NFDM/TBST.
ab181602 was used as a loading control at 1/1000000 dilution.
We recommend involving downstream protein p-MLKL as a control to validate the stimulation of p-RIP3.
Lanes 1 - 4:
Western blot - Anti-RIP3 (phospho S232) antibody [EPR9516(N)-25] (<a href='/products/primary-antibodies/rip3-phospho-s232-antibody-epr9516n-25-ab195117'>ab195117</a>) at 1/1000 dilution
Lanes 5 - 8:
Western blot - Anti-MLKL (phospho S345) antibody [EPR9515(2)] (ab196436) at 1/1000 dilution
Lanes 1, 3, 5 and 7:
Untreated L-929 (mouse connective tissue fibroblast cell line) whole cell lysate at 20 µg
Lanes 2 and 6:
L-929 (mouse connective tissue fibroblast cell line) treated with 20 ng/ml TNF-a, 100 nM Smac mimetic and 20 μM z-VAD for 8 hours whole cell lysate at 20 µg
Lanes 4 and 8:
L-929 (mouse connective tissue fibroblast cell line) treated with 20 ng/ml TNF-a, 100 nM Smac mimetic and 20 μM z-VAD for 6 hours whole cell lysate at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution
Predicted band size: 57 kDa,54 kDa
Observed band size: 53 kDa
false
Exposure time: 180s
- IP
Lab
Immunoprecipitation - Anti-MLKL (phospho S345) antibody [EPR9515(2)] (AB196436)
MLKL (phospho S345) was immunoprecipitated from 1mg of L-929 (Mouse connective tissue fibroblast cells) whole cell lysate treated with 20 ng/ml TNF alpha (ab9642) + 100 nM Smac mimetic + 20 μM z-VAD compound (ab120382) for 8h using ab196436 at 1/150 dilution. Western blot was performed from the immunoprecipitate using ab196436 at 1/1000 dilution. Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG, was used as secondary antibody at 1/1500 dilution.
Lane 1 : L-929 whole cell lysate treated with 20 ng/ml TNF alpha (ab9642) + 100 nM Smac mimetic+ 20 μM z-VAD compound (ab120382) for 8h;10 μg (Input).
Lane 2 : ab196436 IP in L-929 whole cell lysate treated with 20 ng/ml TNF alpha (ab9642) + 100 nM Smac mimetic+ 20 μM z-VAD compound (ab120382) for 8h.
Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab196436 in L-929 whole cell lysate treated with 20 ng/ml TNF alpha (ab9642) + 100 nM Smac mimetic+ 20 μM z-VAD compound (ab120382) for 8h.
Blocking and dilution buffer and concentration : 5% NFDM/TBST.
All lanes:
Immunoprecipitation - Anti-MLKL (phospho S345) antibody [EPR9515(2)] (ab196436)
All lanes:
Immunoprecipitation - Recombinant human TNF alpha protein (<a href='/products/proteins-peptides/recombinant-human-tnf-alpha-protein-ab9642'>ab9642</a>)
Predicted band size: 54 kDa
Observed band size: 54 kDa
false
- Dot
Supplier Data
Dot Blot - Anti-MLKL (phospho S345) antibody [EPR9515(2)] (AB196436)
Dot blot analysis of MLKL (phospho S345) peptide (Lane 1), and non-phospho peptide (Lane 2), labeled using ab196436 at 1/1000 dilution, followed by Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated secondary antibody at 1/1000 dilution.
Blocking and dilution buffer : 5% NFDM/TBST.
Exposure time : 3 minutes.
反应性数据
产品详情
Anti-MLKL (phospho S345) antibody [EPR9515(2)] (ab196436) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in Dot Blot, IP and WB.
Anti-MLKL (phospho S345) antibody [EPR9515(2)] (ab196436) was first used in a scientific publication in 2016 and has been cited over 288 times in peer reviewed journals. It's performance in Western Blot and IHC in mouse samples is trusted by the scientific community.
Abcam's high quality manufacturing and validation processes ensure Anti-MLKL (phospho S345) antibody [EPR9515(2)] (ab196436) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility.
Anti-MLKL (phospho S345) antibody [EPR9515(2)] (ab196436) has 25 independent reviews from customers.
Anti-MLKL (phospho S345) antibody [EPR9515(2)] (ab196436) specifically detects MLKL Phospho-S345 (UniProt ID: Q9D2Y4; Molecular weight: 55kDa) and is sold in 100 µL and 1 mL selling sizes.
Conjugation-ready, carrier free format available for antibody clone EPR9515(2) - ab208910.
Antibody clone EPR9515(2) is also available pre-conjugated to a variety of labels for your convenience - HRP (ab208430).
Mixed lineage kinase domain-like protein (MLKL) is a key executor of necroptosis, a form of programmed cell death and its expression is associated with both tumor suppression and promotion, depending on the cancer type. Its role in necroptosis and other cellular processes makes it a potential prognostic marker and therapeutic target in oncology.
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
性能和储存信息
形式
纯化工艺
存储溶液
运输条件
推荐的短期储存时间
推荐的短期储存条件
推荐的长期储存条件
分装信息
储存信息
补充信息
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
The MLKL protein acts as an executioner of cell death by forming a complex that disrupts the plasma membrane integrity. This process is downstream of receptor-interacting serine/threonine-protein kinase 3 (RIPK3) which phosphorylates MLKL to form the active necrosome complex. Active MLKL oligomerizes and migrates towards the inner leaflet of the plasma membrane binding to phosphatidylinositol phosphates which assists in pore formation and cellular rupture. The ability to measure MLKL activity levels such as via MLKL ELISA kits is important for understanding necrotic processes in detailed studies.
Pathways
MLKL is integrally involved in the necroptotic pathway alongside RIPK1 and RIPK3 which are key initiators of necroptosis. Phosphorylated MLKL acts downstream of RIPK3 resulting in cell death without caspase activation distinguishing necroptosis from apoptosis. MLKL and RIPK3 are tightly linked within this pathway with MLKL phosphorylation serving as a vital event for the execution phase. The necroptosis pathway is part of larger networks including inflammatory response pathways highlighting the importance of MLKL's role beyond sheer cell death.
产品实验方案
- Visit the General protocols
- Visit the Troubleshooting
靶点信息
文献 (404)
Recent publications for all applications. Explore the full list and refine your search
Toxics 13: PubMed41012357
2025
Applications
Unspecified application
Species
Unspecified reactive species
Cell research 35:840-858 PubMed40940518
2025
Applications
Unspecified application
Species
Unspecified reactive species
Cell death discovery 11:413 PubMed40877228
2025
Applications
Unspecified application
Species
Unspecified reactive species
Research (Washington, D.C.) 8:0823 PubMed40822127
2025
Applications
Unspecified application
Species
Unspecified reactive species
Cellular & molecular biology letters 30:87 PubMed40691547
2025
Applications
Unspecified application
Species
Unspecified reactive species
Scientific reports 15:22592 PubMed40595878
2025
Applications
Unspecified application
Species
Unspecified reactive species
Cell death & disease 16:456 PubMed40533460
2025
Applications
Unspecified application
Species
Unspecified reactive species
Cell death & disease 16:426 PubMed40456737
2025
Applications
Unspecified application
Species
Unspecified reactive species
Signal transduction and targeted therapy 10:171 PubMed40404630
2025
Applications
Unspecified application
Species
Unspecified reactive species
PLoS pathogens 21:e1013167 PubMed40359428
2025
Applications
Unspecified application
Species
Unspecified reactive species
Abcam Product Promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com